More surprises in the development of an HIV vaccine

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Esparza, José ^a   Van Regenmortel, Marc H V ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Bacterial adjuvants; HIV vaccine; Inactivated SIV; Lactobacilli; SIV vaccine; Tolerogenic vaccine

Indexed keywords

EID: 84905665255     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00329     Document Type: Note

References (25)

1. Andrieu JM, Chen S, Lai C, Guo W, Lu W. Mucosal SIV vaccines comprising inactivated virus particles and bacterial adjuvants induce CD8+T-regulatory cells that suppress SIV positive CD4+cell activation and prevent SIV infection in the macaque model. Front Immunol. (2014) 5:297. doi:10.3389/fimmu.2014.00297
2. Esparza J. A brief history of the global effort to develop an HIV vaccine. Vaccine (2013) 31:3502-18. doi:10.1016/j.vaccine.2013.05.018
3. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (1982) 298:347-50. doi:10.1038/298347a0
4. AcAleer WJ, Bynak EB, Maigeter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature (1984) 307:178-80. doi:10.1038/307178a0
5. Hilleman MR. A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS. Vaccine (1998) 16:778-93. doi:10.1016/S0264-410X(97)00272-7
6. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: a new 'old' paradigm for HIV vaccines. Clin Vaccine Immunol (2014). doi:10.1128/CVI.00230-14
7. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Engl J Med (2007) 356:2073-81. doi:10.1056/NEJMra066267
8. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet (2008) 372:1881-93. doi:10.1016/S0140-6736(08)61591-3
9. Kaiser J. Review of vaccine failure prompts to basic science. Science (2008) 320:30-1. doi:10.1126/science.320.5872.30
10. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 303:316. doi:10.1126/science.1094620
11. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361:2209-20. doi:10.1056/NEJMoa0908492
12. Letvin NL. Moving forward in HIV vaccine development. Science (2009) 326:1196-8. doi:10.1126/science.1183278
13. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras G, Alam S, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366:1275-86. doi:10.1056/NEJMoa1113425
14. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis (2013) 207:240-7. doi:10.1093/infdis/jis670
15. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 340(6135):1237874. doi:10.1126/science.1237874
16. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (step study). J Infect Dis (2012) 206:258-66. doi:10.1093/infdis/jis342
17. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN503/Phambili study. Lancet Infect Dis (2014) 14:388-96. doi:10.1016/S1473-3099(14)70020-9
18. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Groves D, et al. Efficacy trial of a DNA/rAds HIV-1 preventive vaccine. N Engl J Med (2013) 369:2083-92. doi:10.1056/NEJMoa1310566
19. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP. Immune activation with HIV vaccines. Science (2014) 344:49-51. doi:10.1126/science.1250672
20. Johnston MI, Fauci AS. HIV vaccine development-improving on natural immunity. N Engl J Med (2011) 365:873-5. doi:10.1056/NEJMp1107621
21. Lu W, Chen S, Lai C, Guo W, Andrieu J-M. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 2:1736-46. doi:10.1016/j.celrep.2012.11.016
22. Van Regenmortel MHV. An oral tolerogenic vaccine protects macaques from SIV infection without eliciting SIV-specific antibodies nor CTLs. J AIDS Clin Res (2013) 4:e112. doi:10.4172/2155-6113.1000e112
23. Esparza J. What has 30 years of HIV vaccine research taught us? Vaccines (2013) 1:513-26. doi:10.3390/vaccines1040513
24. Van Regenmortel MHV, Andrieu J-M, Dimitrov DS, Ensoli B, Hioe CE, Moog C, et al. Paradigm changes and the future of HIV vaccines: a summary of a workshop held in Baltimore on 20 November 2013. J AIDS Clin Res (2014) 5:281. doi:10.4172/2155-6113.1000281
25. Simonton DK. After Einstein: scientific genius is extinct. Nature (2013) 493:602. doi:10.1038/493602a